Targeting Plk1 in cutaneous T-cell lymphomas (CTCLs)

Cell Cycle. 2011 May 15;10(10):1523. doi: 10.4161/cc.10.10.15522. Epub 2011 May 15.
No abstract available

Publication types

  • News
  • Comment

MeSH terms

  • Benzimidazoles / therapeutic use
  • Cell Cycle Proteins / antagonists & inhibitors*
  • Cell Cycle Proteins / genetics
  • Cell Cycle Proteins / metabolism
  • Cell Division
  • Cell Line, Tumor
  • Cyclin B1 / metabolism
  • G2 Phase
  • Humans
  • Lymphoma, T-Cell, Cutaneous / drug therapy*
  • Lymphoma, T-Cell, Cutaneous / metabolism
  • Polo-Like Kinase 1
  • Protein Serine-Threonine Kinases / antagonists & inhibitors*
  • Protein Serine-Threonine Kinases / genetics
  • Protein Serine-Threonine Kinases / metabolism
  • Proto-Oncogene Proteins / antagonists & inhibitors*
  • Proto-Oncogene Proteins / genetics
  • Proto-Oncogene Proteins / metabolism
  • RNA Interference
  • RNA, Small Interfering / metabolism
  • Thiophenes / therapeutic use
  • cdc25 Phosphatases / metabolism

Substances

  • 5-(5,6-dimethoxy-1H-benzimidazol-1-yl)-3-((2-(trifluoromethyl)benzyl)oxy)thiophene-2-carboxamide
  • Benzimidazoles
  • Cell Cycle Proteins
  • Cyclin B1
  • Proto-Oncogene Proteins
  • RNA, Small Interfering
  • Thiophenes
  • Protein Serine-Threonine Kinases
  • CDC25C protein, human
  • cdc25 Phosphatases